{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:47:22Z","timestamp":1788346042027,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI139276"],"award-info":[{"award-number":["R01 AI139276"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R44 AI150060"],"award-info":[{"award-number":["R44 AI150060"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The expansion of Lyme borreliosis endemic areas and the corresponding increase of disease incidence have opened the possibility for greater acceptance of a vaccine. In this perspective article, we discuss the discovery of outer surface protein A (OspA) of\n                    <jats:italic>B. burgdorferi<\/jats:italic>\n                    , and the subsequent pre-clinical testing and clinical trials of a recombinant OspA vaccine for human Lyme disease. We also discuss in detail the open public hearings of the FDA Lyme disease vaccine advisory panel held in 1998 where concerns of molecular mimicry induced autoimmunity to native OspA were raised, the limitations of those studies, and the current modifications of recombinant OspA to develop a multivalent subunit vaccine for Lyme disease.\n                  <\/jats:p>","DOI":"10.1038\/s41541-022-00429-5","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T06:03:15Z","timestamp":1643263395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["The year that shaped the outcome of the OspA vaccine for human Lyme disease"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1983-1301","authenticated-orcid":false,"given":"Raymond J.","family":"Dattwyler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3715-4543","authenticated-orcid":false,"given":"Maria","family":"Gomes-Solecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"429_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/archderm.1970.04000070106017","volume":"102","author":"RJ Scrimenti","year":"1970","unstructured":"Scrimenti, R. J. Erythema chronicum migrans. Arch. Dermatol. 102, 104\u2013105 (1970).","journal-title":"Arch. Dermatol."},{"key":"429_CR2","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.236.21.2392d","volume":"236","author":"WE Mast","year":"1976","unstructured":"Mast, W. E. & Burrows, W. M. Erythema chronicum migrans and \u201cLyme arthritis\u201d. JAMA 236, 2392 (1976).","journal-title":"JAMA"},{"key":"429_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.1780200102","volume":"20","author":"AC Steere","year":"1977","unstructured":"Steere, A. C. et al. Lyme arthritis: An epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum. 20, 7\u201317 (1977a).","journal-title":"Arthritis Rheum."},{"key":"429_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.7326\/0003-4819-86-6-685","volume":"86","author":"AC Steere","year":"1977","unstructured":"Steere, A. C. et al. Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum. Ann. Intern. Med. 86, 685\u2013698 (1977).","journal-title":"Ann. Intern. Med."},{"key":"429_CR5","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.7043737","volume":"216","author":"W Burgdorfer","year":"1982","unstructured":"Burgdorfer, W. et al. Lyme disease-a tick-borne spirochetosis? Science 216, 1317\u20131319 (1982).","journal-title":"Science"},{"key":"429_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJM198303313081302","volume":"308","author":"JL Benach","year":"1983","unstructured":"Benach, J. L. et al. Spirochetes isolated from the blood of two patients with Lyme disease. N. Engl. J. Med. 308, 740\u2013742 (1983).","journal-title":"N. Engl. J. Med."},{"key":"429_CR7","first-page":"581","volume":"57","author":"AG Barbour","year":"1984","unstructured":"Barbour, A. G. Immunochemical analysis of Lyme disease spirochetes. Yale J. Biol. Med. 57, 581\u2013586 (1984).","journal-title":"Yale J. Biol. Med."},{"key":"429_CR8","first-page":"521","volume":"57","author":"AG Barbour","year":"1984","unstructured":"Barbour, A. G. Isolation and cultivation of Lyme disease spirochetes. Yale J. Biol. Med. 57, 521\u2013525 (1984).","journal-title":"Yale J. Biol. Med."},{"key":"429_CR9","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1126\/science.3969554","volume":"227","author":"TR Howe","year":"1985","unstructured":"Howe, T. R., Mayer, L. W. & Barbour, A. G. A single recombinant plasmid expressing two major outer surface proteins of the Lyme disease spirochete. Science 227, 645\u2013646 (1985).","journal-title":"Science"},{"key":"429_CR10","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1073\/pnas.87.10.3768","volume":"87","author":"UE Schaible","year":"1990","unstructured":"Schaible, U. E. et al. Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc. Natl Acad. Sci. USA 87, 3768\u20133772 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"429_CR11","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/eji.1830211016","volume":"21","author":"UE Schaible","year":"1991","unstructured":"Schaible, U. E., Kramer, M. D., Wallich, R., Tran, T. & Simon, M. M. Experimental Borrelia burgdorferi infection in inbred mouse strains: Antibody response and association of H-2 genes with resistance and susceptibility to development of arthritis. Eur. J. Immunol. 21, 2397\u20132405 (1991).","journal-title":"Eur. J. Immunol."},{"key":"429_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1126\/science.2237407","volume":"250","author":"E Fikrig","year":"1990","unstructured":"Fikrig, E., Barthold, S. W., Kantor, F. S. & Flavell, R. A. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 250, 553\u2013556 (1990).","journal-title":"Science"},{"key":"429_CR13","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1073\/pnas.89.12.5418","volume":"89","author":"E Fikrig","year":"1992","unstructured":"Fikrig, E. et al. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc. Natl Acad. Sci. USA 89, 5418\u20135421 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"429_CR14","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/S0264-410X(97)00133-3","volume":"15","author":"MT Philipp","year":"1997","unstructured":"Philipp, M. T. et al. The outer surface protein A (OspA) vaccine against Lyme disease: Efficacy in the rhesus monkey. Vaccine 15, 1872\u20131887 (1997).","journal-title":"Vaccine"},{"key":"429_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1084\/jem.183.1.271","volume":"183","author":"AM de Silva","year":"1996","unstructured":"de Silva, A. M., Telford, S. R. 3rd, Brunet, L. R., Barthold, S. W. & Fikrig, E. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J. Exp. Med. 183, 271\u2013275 (1996).","journal-title":"J. Exp. Med."},{"key":"429_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/infdis\/167.1.165","volume":"167","author":"A Sadziene","year":"1993","unstructured":"Sadziene, A., Thompson, P. A. & Barbour, A. G. In vitro inhibition of Borrelia burgdorferi growth by antibodies. J. Infect. Dis. 167, 165\u2013172 (1993).","journal-title":"J. Infect. Dis."},{"key":"429_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1128\/IAI.67.1.30-35.1999","volume":"67","author":"AM de Silva","year":"1999","unstructured":"de Silva, A. M. et al. Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks. Infect. Immun. 67, 30\u201335 (1999).","journal-title":"Infect. Immun."},{"key":"429_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1172\/JCI9427","volume":"106","author":"U Pal","year":"2000","unstructured":"Pal, U. et al. Attachment of Borrelia burgdorferi within Ixodes scapularis mediated by outer surface protein A. J. Clin. Invest. 106, 561\u2013569 (2000).","journal-title":"J. Clin. Invest."},{"key":"429_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2004.10.027","volume":"119","author":"U Pal","year":"2004","unstructured":"Pal, U. et al. TROSPA, an Ixodes scapularis receptor for Borrelia burgdorferi. Cell 119, 457\u2013468 (2004).","journal-title":"Cell"},{"key":"429_CR20","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1128\/IAI.73.3.1644-1647.2005","volume":"73","author":"CL Gipson","year":"2005","unstructured":"Gipson, C. L. & de Silva, A. M. Interactions of OspA monoclonal antibody C3.78 with Borrelia burgdorferi within ticks. Infect. Immun. 73, 1644\u20131647 (2005).","journal-title":"Infect. Immun."},{"key":"429_CR21","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJM199610243351703","volume":"335","author":"MA Gerber","year":"1996","unstructured":"Gerber, M. A., Shapiro, E. D., Burke, G. S., Parcells, V. J. & Bell, G. L. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. N. Engl. J. Med. 335, 1270\u20131274 (1996).","journal-title":"N. Engl. J. Med."},{"key":"429_CR22","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.idc.2005.07.007","volume":"19","author":"L Hu","year":"2005","unstructured":"Hu, L. Lyme arthritis. Infect. Dis. Clin. North Am. 19, 947\u2013961 (2005).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"429_CR23","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1056\/NEJMra072023","volume":"357","author":"HM Feder Jr.","year":"2007","unstructured":"Feder, H. M. Jr. et al. A critical appraisal of \u201cchronic Lyme disease\u201d. N. Engl. J. Med. 357, 1422\u20131430 (2007).","journal-title":"N. Engl. J. Med."},{"key":"429_CR24","doi-asserted-by":"publisher","first-page":"e0198509","DOI":"10.1371\/journal.pone.0198509","volume":"13","author":"KO Johnson","year":"2018","unstructured":"Johnson, K. O. et al. Clinical manifestations of reported Lyme disease cases in Ontario, Canada: 2005\u20132014. PLoS One 13, e0198509 (2018).","journal-title":"PLoS One"},{"key":"429_CR25","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1002\/art.22131","volume":"54","author":"AC Steere","year":"2006","unstructured":"Steere, A. C. & Angelis, S. M. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum. 54, 3079\u20133086 (2006).","journal-title":"Arthritis Rheum."},{"key":"429_CR26","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1128\/iai.61.7.2774-2779.1993","volume":"61","author":"RA Kalish","year":"1993","unstructured":"Kalish, R. A., Leong, J. M. & Steere, A. C. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect. Immun. 61, 2774\u20132779 (1993).","journal-title":"Infect. Immun."},{"key":"429_CR27","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1084\/jem.180.6.2069","volume":"180","author":"B Lengl-Janssen","year":"1994","unstructured":"Lengl-Janssen, B., Strauss, A. F., Steere, A. C. & Kamradt, T. The T helper cell response in Lyme arthritis: differential recognition of Borrelia burgdorferi outer surface protein A in patients with treatment-resistant or treatment-responsive Lyme arthritis. J. Exp. Med. 180, 2069\u20132078 (1994).","journal-title":"J. Exp. Med."},{"key":"429_CR28","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1002\/1529-0131(199912)42:12<2705::AID-ANR29>3.0.CO;2-H","volume":"42","author":"D Carlson","year":"1999","unstructured":"Carlson, D. et al. Lack of Borrelia burgdorferi DNA in synovial samples from patients with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 42, 2705\u20132709 (1999).","journal-title":"Arthritis Rheum."},{"key":"429_CR29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1126\/science.281.5377.703","volume":"281","author":"DM Gross","year":"1998","unstructured":"Gross, D. M. et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281, 703\u2013706 (1998).","journal-title":"Science"},{"key":"429_CR30","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.4049\/jimmunol.157.12.5496","volume":"157","author":"LK Bockenstedt","year":"1996","unstructured":"Bockenstedt, L. K., Fikrig, E., Barthold, S. W., Flavell, R. A. & Kantor, F. S. Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice. J. Immunol. 157, 5496\u20135502 (1996).","journal-title":"J. Immunol."},{"key":"429_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ni0901-797","volume":"2","author":"C Benoist","year":"2001","unstructured":"Benoist, C. & Mathis, D. Autoimmunity provoked by infection: How good is the case for T cell epitope mimicry? Nat. Immunol. 2, 797\u2013801 (2001).","journal-title":"Nat. Immunol."},{"key":"429_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0167-5699(98)01299-7","volume":"19","author":"D Mason","year":"1998","unstructured":"Mason, D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 19, 395\u2013404 (1998).","journal-title":"Immunol. Today"},{"key":"429_CR33","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.4049\/jimmunol.160.8.3631","volume":"160","author":"B Hemmer","year":"1998","unstructured":"Hemmer, B. et al. Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J. Immunol. 160, 3631\u20133636 (1998).","journal-title":"J. Immunol."},{"key":"429_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0167-5699(97)01217-6","volume":"19","author":"B Hemmer","year":"1998","unstructured":"Hemmer, B., Vergelli, M., Pinilla, C., Houghten, R. & Martin, R. Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol. Today 19, 163\u2013168 (1998).","journal-title":"Immunol. Today"},{"key":"429_CR35","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/1521-4141(200002)30:2<448::AID-IMMU448>3.0.CO;2-9","volume":"30","author":"B Maier","year":"2000","unstructured":"Maier, B. et al. Multiple cross-reactive self-ligands for Borrelia burgdorferi-specific HLA-DR4-restricted T cells. Eur. J. Immunol. 30, 448\u2013457 (2000).","journal-title":"Eur. J. Immunol."},{"key":"429_CR36","unstructured":"Steere, A. C. & Baxter-Lowe, L. A. Association of chronic, treatment-resistant Lyme arthritis with rheumatoid arthritis (RA) alleles. Arthritis Rheum. 41, S81 (1998)."},{"key":"429_CR37","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1001\/jama.1994.03510460056033","volume":"271","author":"D Keller","year":"1994","unstructured":"Keller, D. et al. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 271, 1764\u20131768 (1994).","journal-title":"JAMA"},{"key":"429_CR38","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/infdis\/172.5.1324","volume":"172","author":"RT Schoen","year":"1995","unstructured":"Schoen, R. T. et al. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J. Infect. Dis. 172, 1324\u20131329 (1995).","journal-title":"J. Infect. Dis."},{"key":"429_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJM199807233390401","volume":"339","author":"AC Steere","year":"1998","unstructured":"Steere, A. C. et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N. Engl. J. Med. 339, 209\u2013215 (1998).","journal-title":"N. Engl. J. Med."},{"key":"429_CR40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJM199807233390402","volume":"339","author":"LH Sigal","year":"1998","unstructured":"Sigal, L. H. et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant outer-surface protein A Lyme disease vaccine study consortium. N. Engl. J. Med. 339, 216\u2013222 (1998).","journal-title":"N. Engl. J. Med."},{"key":"429_CR41","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1128\/iai.62.10.4632-4636.1994","volume":"62","author":"JJ Weis","year":"1994","unstructured":"Weis, J. J., Ma, Y. & Erdile, L. F. Biological activities of native and recombinant Borrelia burgdorferi outer surface protein A: Dependence on lipid modification. Infect. Immun. 62, 4632\u20134636 (1994).","journal-title":"Infect. Immun."},{"key":"429_CR42","first-page":"2555","volume":"28","author":"CD Rose","year":"2001","unstructured":"Rose, C. D., Fawcett, P. T. & Gibney, K. M. Arthritis following recombinant outer surface protein A vaccination for Lyme disease. J. Rheumatol. 28, 2555\u20132557 (2001).","journal-title":"J. Rheumatol."},{"key":"429_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0149-2918(00)80035-1","volume":"22","author":"RT Schoen","year":"2000","unstructured":"Schoen, R. T. et al. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clin. Ther. 22, 315\u2013325 (2000).","journal-title":"Clin. Ther."},{"key":"429_CR44","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0149-2918(03)90027-0","volume":"25","author":"RT Schoen","year":"2003","unstructured":"Schoen, R. T., Deshefy-Longhi, T., Van-Hoecke, C., Buscarino, C. & Fikrig, E. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine. Clin. Ther. 25, 210\u2013224 (2003).","journal-title":"Clin. Ther."},{"key":"429_CR45","doi-asserted-by":"publisher","first-page":"s259","DOI":"10.1093\/cid\/ciq117","volume":"52","author":"AC Steere","year":"2011","unstructured":"Steere, A. C., Drouin, E. E. & Glickstein, L. J. Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin. Infect. Dis. 52, s259\u2013s265 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"429_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3855\/jidc.7999","volume":"11","author":"H Zhao","year":"2017","unstructured":"Zhao, H., Bao, F. F. & Liu, A. Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis. J. Infect. Dev. Ctries 11, 1\u20139 (2017).","journal-title":"J. Infect. Dev. Ctries"},{"key":"429_CR47","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.17269\/CJPH.108.5728","volume":"108","author":"A Badawi","year":"2017","unstructured":"Badawi, A., Shering, M., Rahman, S. & Lindsay, L. R. A systematic review and meta-analysis for the adverse effects, immunogenicity, and efficacy of Lyme disease vaccines: Guiding novel vaccine development. Can. J. Public Health 108, e62\u2013e70 (2017).","journal-title":"Can. J. Public Health"},{"key":"429_CR48","unstructured":"Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting. Open Public Hearing on LYMErix, recombinant Lipoproteins OspA Lyme Vaccine from SmithKIine Beecham Pharmaceuticals. Court Transcript. Neal R. Gross, Court Reporters and Transcribers, 1\u2013325. https:\/\/962b5f1f-2df4-46ae-a813-250638ec1c9e.filesusr.com\/ugd\/47b066_a772f2892cfd41a4915d27f6112148a7.pdf (1998)."},{"key":"429_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0950268806007096","volume":"135","author":"LE Nigrovic","year":"2007","unstructured":"Nigrovic, L. E. & Thompson, K. M. The Lyme vaccine: A cautionary tale. Epidemiol. Infect. 135, 1\u20138 (2007).","journal-title":"Epidemiol. Infect."},{"key":"429_CR50","doi-asserted-by":"publisher","first-page":"413","DOI":"10.7326\/0003-4819-136-5-200203050-00024","volume":"136","author":"LH Sigal","year":"2002","unstructured":"Sigal, L. H. Misconceptions about Lyme disease: Confusions hiding behind ill-chosen terminology. Ann. Intern. Med. 136, 413\u2013419 (2002).","journal-title":"Ann. Intern. Med."},{"key":"429_CR51","doi-asserted-by":"publisher","first-page":"s253","DOI":"10.1093\/cid\/ciq116","volume":"52","author":"GA Poland","year":"2011","unstructured":"Poland, G. A. Vaccines against Lyme disease: What happened and what lessons can we learn? Clin. Infect. Dis. 52, s253\u2013s258 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"429_CR52","doi-asserted-by":"publisher","first-page":"s271","DOI":"10.1093\/cid\/ciq119","volume":"52","author":"SA Plotkin","year":"2011","unstructured":"Plotkin, S. A. Correcting a public health fiasco: The need for a new vaccine against Lyme disease. Clin. Infect. Dis. 52, s271\u2013s275 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"429_CR53","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S1473-3099(11)70034-2","volume":"11","author":"PG Auwaerter","year":"2011","unstructured":"Auwaerter, P. G. et al. Antiscience and ethical concerns associated with advocacy of Lyme disease. Lancet Infect. Dis. 11, 713\u2013719 (2011).","journal-title":"Lancet Infect. Dis."},{"key":"429_CR54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/jme.2009.032896","volume":"37","author":"PG Auwaerter","year":"2011","unstructured":"Auwaerter, P. G. et al. Scientific evidence and best patient care practices should guide the ethics of Lyme disease activism. J. Med. Ethics 37, 68\u201373 (2011).","journal-title":"J. Med. Ethics"},{"key":"429_CR55","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1468-0009.2012.00663.x","volume":"90","author":"RA Aronowitz","year":"2012","unstructured":"Aronowitz, R. A. The rise and fall of the Lyme disease vaccines: a cautionary tale for risk interventions in American medicine and public health. Milbank Q. 90, 250\u2013277 (2012).","journal-title":"Milbank Q."},{"key":"429_CR56","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1073\/pnas.0305680101","volume":"101","author":"TA Willett","year":"2004","unstructured":"Willett, T. A., Meyer, A. L., Brown, E. L. & Huber, B. T. An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc. Natl Acad. Sci. USA 101, 1303\u20131308 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"429_CR57","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1128\/CVI.00169-08","volume":"15","author":"B del Rio","year":"2008","unstructured":"del Rio, B. et al. Oral immunization with recombinant lactobacillus plantarum induces a protective immune response in mice with Lyme disease. Clin. Vaccines Immunol. 15, 1429\u20131435 (2008).","journal-title":"Clin. Vaccines Immunol."},{"key":"429_CR58","unstructured":"Dattwyler, R. J., Gomes-Solecki, M. J. C., Luft, B. J. & Dunn, J. J. Recombinant Constructs of Borrelia burgdorferi. USPTO full text and image database. Patent numbers: 7,008,625; 7,179,448; 7,606,248 (2006)."},{"key":"429_CR59","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S1473-3099(13)70110-5","volume":"13","author":"N Wressnigg","year":"2013","unstructured":"Wressnigg, N. et al. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1\/2 trial. Lancet Infect. Dis. 13, 680\u2013689 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"429_CR60","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jmb.2005.04.066","volume":"350","author":"S Koide","year":"2005","unstructured":"Koide, S., Yang, X., Huang, X., Dunn, J. J. & Luft, B. J. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. J. Mol. Biol. 350, 290\u2013299 (2005).","journal-title":"J. Mol. Biol."},{"key":"429_CR61","doi-asserted-by":"publisher","first-page":"e0184357","DOI":"10.1371\/journal.pone.0184357","volume":"12","author":"P Comstedt","year":"2017","unstructured":"Comstedt, P., Schuler, W., Meinke, A. & Lundberg, U. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. PLoS One 12, e0184357 (2017).","journal-title":"PLoS One"},{"key":"429_CR62","unstructured":"VLA15. Ongoing Clinical Trials. https:\/\/clinicaltrials.gov\/ct2\/results?term=vaccine&cond=Lyme+Disease (2020)."},{"key":"429_CR63","unstructured":"Release, Press. P. Valneva and Pfizer announce collaboration to co-develop and commercialize Lyme Disease Vaccine, VLA15. Pfizer Press Releases. https:\/\/valneva.com\/press-release\/valneva-and-pfizer-announce-collaboration-to-co-develop-and-commercialize-lyme-disease-vaccine-vla15\/ (2020)."},{"key":"429_CR64","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/cid\/ciz872","volume":"70","author":"M Gomes-Solecki","year":"2020","unstructured":"Gomes-Solecki, M. et al. Protective immunity and new vaccines for Lyme disease. Clin. Infect. Dis. 70, 1768\u20131773 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"429_CR65","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/infdis\/jiy627","volume":"219","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Anti-OspA DNA-encoded monoclonal antibody prevents transmission of spirochetes in tick challenge providing sterilizing immunity in mice. J. Infect. Dis. 219, 1146\u20131150 (2019).","journal-title":"J. Infect. Dis."},{"key":"429_CR66","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1080\/21645515.2020.1789408","volume":"16","author":"GH Guibinga","year":"2020","unstructured":"Guibinga, G. H. et al. Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine. Hum. Vaccines Immunother. 16, 2114\u20132122 (2020).","journal-title":"Hum. Vaccines Immunother."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00429-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00429-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00429-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T17:55:23Z","timestamp":1674582923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00429-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00429-5","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"13 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: M.G.S. (stocks, patents), R.J.D. (stocks, patents). M.G.S. and R.J.D. have no financial interests in Valneva\/Pfizer and were not commissioned by any private or public sources to write this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}